Dental Care Clinics in Carnegie, PA Accepting Medicare
2 Dental Care Clinics found. Showing 1 - 2
 General Service And Supply Inc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 2323 Greentree Rd, Carnegie, PA 15106 Phone: 412-279-4114 Fax: 412-279-6139 |
West Penn Dental Center Llc Dentist Medicare: Not Enrolled in Medicare Practice Location: 312 Second Avenue, Carnegie, PA 15106 Phone: 412-279-7366 Fax: 412-279-6668 |
News Archive
New drug could significantly slow progression of ALS, shows research
A new drug could significantly slow the progression of ALS, also known as Lou Gehrig's disease, according to new research by University of Alberta biologists. Current treatments slow progression of the degenerative disease by only a few months, and these findings could revolutionize the treatment of patients suffering from ALS, extending and improving quality of life.
Novel cell sorting enhancement to MoFlo Astrios platform to be introduced by Beckman Coulter Life Sciences at CYTO 2013
Two seminars and seven poster sessions, Beckman Coulter will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.
FDA approves St. Jude Medical's Unify CRT-D and Fortify ICD devices
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) approval and first U.S. implants of its Unify™ cardiac resynchronization therapy defibrillator (CRT-D) and Fortify™ implantable cardioverter defibrillator (ICD). The new devices feature advanced battery technology and circuitry that allow for the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity or power.
Researchers identify gene variants that substantially increase risk for schizophrenia
Schizophrenia has long been known to be highly heritable and is present in approximately 1% of the population. Researchers have been following two paths in their pursuit of identifying schizophrenia risk genes.
Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by its collaboration partner AstraZeneca.
› Verified 7 days ago